Tanushka Dutta
- All
- News
- Videos
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Air India's Flight To Nowhere: Wrong Plane, 8 Hours In Air, And A U-Turn
The aircraft was a Boeing 777-200LR, while Air India currently has approval to operate only its Boeing 777-300ER fleet on services to Canada.
-
"High-Risk Environment": India Asks Airlines To Avoid 11 Airspaces Amid Iran War
The identified high-risk zone includes airspace over Iran, Israel, Lebanon, Saudi Arabia, Bahrain, Oman, Iraq, Jordan, the UAE, Qatar and Kuwait, covering all flight levels.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
"Illegal, Unjustifed": Russia Diplomat On US-Israel's Attack On Iran
Russia has strongly condemned the US-Israel war against Iran, warning of global instability, volatile oil prices and disruptions to critical supply routes like the Strait of Hormuz.
-
"No Consultation With States": Congress Raises Concerns Over New Education Bill
The Viksit Bharat Shiksha Adhishthan (VBSA) Bill, 2025, is part of the Centre's plan to restructure higher education regulation by replacing existing bodies with a new framework. The proposed law is under review by a parliamentary panel.
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
In Big Relief For Flyers, Centre Says No Selection Fee On 60% Seats
Keep Atleast 60% Seats On Flights Free Of Cost: Government Tells Airlines
-
'What Good Is My Win If Ladakh Loses?' Sonam Wangchuk After Release From Jail
The innovator-activist walked out of Jodhpur Central Jail on Saturday after the Centre revoked his detention under the National Security Act (NSA).
-
PM-Vidyalaxmi Completes One Year With 50 Per Cent Loan Approval Rate On Portal, Rs 36,000 Crore Sanctioned
PM-Vidyalaxmi Scheme: The scheme is limited to students admitted to Quality Higher Education Institutions identified through NIRF rankings. This includes all central government institutions.
-
Ozempic Copycats Arrive: From Rs 11,000 To Rs 3,000, How Patent Expiry Is Reshaping Diabetes Treatment
With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy expected at around Rs 3,000 to Rs 4,000 for initial doses
-
Air India's Flight To Nowhere: Wrong Plane, 8 Hours In Air, And A U-Turn
The aircraft was a Boeing 777-200LR, while Air India currently has approval to operate only its Boeing 777-300ER fleet on services to Canada.
-
"High-Risk Environment": India Asks Airlines To Avoid 11 Airspaces Amid Iran War
The identified high-risk zone includes airspace over Iran, Israel, Lebanon, Saudi Arabia, Bahrain, Oman, Iraq, Jordan, the UAE, Qatar and Kuwait, covering all flight levels.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
"Illegal, Unjustifed": Russia Diplomat On US-Israel's Attack On Iran
Russia has strongly condemned the US-Israel war against Iran, warning of global instability, volatile oil prices and disruptions to critical supply routes like the Strait of Hormuz.
-
"No Consultation With States": Congress Raises Concerns Over New Education Bill
The Viksit Bharat Shiksha Adhishthan (VBSA) Bill, 2025, is part of the Centre's plan to restructure higher education regulation by replacing existing bodies with a new framework. The proposed law is under review by a parliamentary panel.
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
In Big Relief For Flyers, Centre Says No Selection Fee On 60% Seats
Keep Atleast 60% Seats On Flights Free Of Cost: Government Tells Airlines
-
'What Good Is My Win If Ladakh Loses?' Sonam Wangchuk After Release From Jail
The innovator-activist walked out of Jodhpur Central Jail on Saturday after the Centre revoked his detention under the National Security Act (NSA).
-
PM-Vidyalaxmi Completes One Year With 50 Per Cent Loan Approval Rate On Portal, Rs 36,000 Crore Sanctioned
PM-Vidyalaxmi Scheme: The scheme is limited to students admitted to Quality Higher Education Institutions identified through NIRF rankings. This includes all central government institutions.
